trending Market Intelligence /marketintelligence/en/news-insights/trending/wxznhoseki6hpb9-i_glow2 content esgSubNav
In This List

Merck & Co. licenses Nasonex to Perrigo

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Merck & Co. licenses Nasonex to Perrigo

New Jersey's Merck & Co. Inc. licensed Nasonex, a prescription-only nasal spray for allergies, to Dublin-based Perrigo Co. plc.

Financial terms of the agreement were not disclosed.

With the exclusive license, Perrigo may market a nonprescription version of Nasonex in the U.S. The company still needs to secure regulatory approvals for the over-the-counter, or OTC, product.

"We are working diligently to bring this important product to consumers and customers more quickly than the average five-year OTC switch time frame," Perrigo President and CEO Uwe Roehrhoff said in a news release.

Prescription brand and generic market sales for Nasonex across the 12 months ended June reached about $214 million.